Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (5437)	5/31/1998 10:48:00 AM
From: BK	Read Replies (1) \| Respond to of 29382

Needleless injections have been around for some time. However, if the company is touting them as "painless", they really need to reconsider. The Armed Services use an "air gun" device which attaches to the bottle of vaccine. The end of the gun is placed next to the shoulder and you get "shot". Problems with the system - everyone gets the same dosage (a 98 lb female and a 250 lg male get the same). While getting the shot, the gun must remain stiff against the arm, or there is a possibility of "cutting" from the air pressure. Don't think anybody in the Armed Forces thought about the contamination angle, but they knew it was a lot quicker than needles. I have received flu vaccinations using this method and the arm was sore for quite some time. Bruce

To: Sergio H who wrote (5437)	5/31/1998 11:49:00 AM
From: James Strauss	Respond to of 29382

BJCT... Sergio: Excellent analysis... Here is a snipit from the latest news release: >>> Said Jim O'Shea, chairman, president, and chief executive officer of Bioject: "Our results represent a shift in our strategic focus toward building corporate alliances that we expect will create lucrative new markets for our technologies. We're making considerable progress on this front, with a number of near- and long-term prospects currently under review. In March, we strengthened our position in the home-use market with the acquisition of Vitajet, a manufacturer of personal use needle-free injectors. Furthermore, our blood glucose-monitoring project is advancing on schedule, with our first pre-clinical trial -- conducted in April -- yielding encouraging results." Said Mike Temple, chief financial officer of Bioject, "As part of our strategic realignment, we have reduced our direct sales force and will focus on leveraging the sales and marketing capabilities of our corporate partners. Going forward, we anticipate this realignment will produce significant cost savings in the Company's needle-free business segment, as we continue to develop distribution alliances with Hoffmann-LaRoche and other potential partners." Bioject develops, manufactures and markets jet injection systems for needle-free drug delivery. The Company's advanced injection management system, the Biojector 2000, has received the Seal of Acceptance from the Alliance of Children's Hospitals, Inc. The Company is developing a system for Hoffmann-La Roche to market specifically with their products. Bioject is also developing an ambulatory continuous blood glucose-monitoring system for diabetics through a joint venture with Elan Corporation.<<< ********************************************************************** This was an 8.00 stock in the early 90's... A look at a long term chart shows the upward breakout of a multi-year downtrend... The insider buying points to those "in the know" seeing a positive turnaround for the company... a 5.00 to 6.00 price in the intermediate term seems reasonable... Jim